157 related articles for article (PubMed ID: 37900431)
1. Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan.
Naya N; Oka H; Hashimoto S; Morioka Y; Kizawa Y
Cureus; 2023 Sep; 15(9):e46090. PubMed ID: 37900431
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
Takata K; Nakazawa M; Honda K; Hashimoto S
Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
[TBL] [Abstract][Full Text] [Related]
3. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
Hale ME; Wild JE; Yamada T; Yokota T; Tack J; Andresen V; Drewes AM
Therap Adv Gastroenterol; 2021; 14():17562848211032320. PubMed ID: 34377150
[TBL] [Abstract][Full Text] [Related]
4. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
6. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
[TBL] [Abstract][Full Text] [Related]
8. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
Webster LR; Hale ME; Yamada T; Wild JE
J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
[TBL] [Abstract][Full Text] [Related]
9. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.
Osaka I; Ishiki H; Yokota T; Tada Y; Sato H; Okamoto M; Satomi E
ESMO Open; 2019; 4(4):e000527. PubMed ID: 31423335
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
[No Abstract] [Full Text] [Related]
12. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
[No Abstract] [Full Text] [Related]
13. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
15. Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.
BouSaba J; Sannaa W; Camilleri M
Therap Adv Gastroenterol; 2022; 15():17562848221078638. PubMed ID: 35509419
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
[No Abstract] [Full Text] [Related]
18. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
19. Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.
Kessoku T; Higashibata T; Morioka Y; Naya N; Koretaka Y; Ichikawa Y; Hisanaga T; Nakajima A
Cureus; 2024 Mar; 16(3):e55925. PubMed ID: 38601408
[TBL] [Abstract][Full Text] [Related]
20. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]